Nano Cap New Millennium Growth Fund L P Buys New Stake in 10x Genomics $TXG

Nano Cap New Millennium Growth Fund L P bought a new stake in shares of 10x Genomics (NASDAQ:TXG) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 30,000 shares of the company’s stock, valued at approximately $489,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Geneos Wealth Management Inc. acquired a new position in shares of 10x Genomics during the 4th quarter valued at $38,000. Larson Financial Group LLC boosted its holdings in 10x Genomics by 164.4% in the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock worth $39,000 after acquiring an additional 1,470 shares during the period. Abich Financial Wealth Management LLC purchased a new position in 10x Genomics in the 3rd quarter worth approximately $56,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in 10x Genomics by 28.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,660 shares of the company’s stock worth $92,000 after acquiring an additional 1,237 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after acquiring an additional 5,025 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Activity at 10x Genomics

In related news, CFO Adam Taich sold 8,968 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total transaction of $166,625.44. Following the completion of the transaction, the chief financial officer owned 288,417 shares in the company, valued at $5,358,787.86. The trade was a 3.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $19.13, for a total value of $191,300.00. Following the transaction, the chief executive officer owned 1,177,273 shares of the company’s stock, valued at $22,521,232.49. This represents a 0.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 46,426 shares of company stock worth $902,695 in the last 90 days. 8.84% of the stock is currently owned by company insiders.

10x Genomics Stock Performance

10x Genomics stock opened at $24.68 on Friday. 10x Genomics has a 1 year low of $8.06 and a 1 year high of $26.44. The company has a market cap of $3.13 billion, a P/E ratio of -145.18 and a beta of 2.05. The firm’s 50-day moving average is $21.58 and its 200-day moving average is $19.58.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.19. 10x Genomics had a negative return on equity of 2.86% and a negative net margin of 3.55%.The business had revenue of $150.84 million during the quarter, compared to analyst estimates of $146.41 million. During the same quarter in the previous year, the firm posted ($0.28) EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, sell-side analysts predict that 10x Genomics will post -0.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TXG. Morgan Stanley lifted their price target on shares of 10x Genomics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Tuesday, May 12th. Leerink Partners dropped their price target on shares of 10x Genomics from $22.00 to $20.00 and set a “market perform” rating for the company in a research note on Tuesday, January 27th. Barclays lifted their price target on shares of 10x Genomics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 14th. Citigroup upped their price objective on 10x Genomics from $18.00 to $24.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. Finally, Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $23.17.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.